Ultrafast Quantitative pH MRI for Acute Ischemic Stroke Patients

用于急性缺血性中风患者的超快定量 pH MRI

• 批准号: 10553103
• 负责人: Hye Young Heo
• 金额: $ 38.48万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-02-15 至 2025-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10553103
• 关键词: 3-Dimensional; Acceleration; Acidosis; Acute; Alteplase; Amides; Animal Model; Animals; Area; Benign; Brain hemorrhage; Brain imaging; Brain region; Cause of Death; Chemicals; Clinic; Clinical; Clinical Trials; Decision Making; Diffusion; Diffusion Magnetic Resonance Imaging; Eligibility Determination; Excision; Frequencies; Goals; Hemorrhage; Hour; Human; Image; Imaging Techniques; Incidence; Infarction; Intervention; Intravenous; Ischemia; Ischemic Penumbra; Ischemic Stroke; Magnetic Resonance Imaging; Metabolism; Methods; Morbidity - disease rate; Outcome; Patient Selection; Patients; Perfusion; Physiologic pulse; Physiological; Population; Probability; Protocols documentation; Protons; Reperfusion Therapy; Research Proposals; Retrospective Studies; Risk; Scanning; Selection for Treatments; Sensitivity and Specificity; Signal Transduction; Speed; Stroke; Symptoms; Techniques; Testing; Therapeutic; Therapeutic Intervention; Time; Tissues; Training; Translating; Translations; United States; Variant; Visualization; Work; acute stroke; blood-brain barrier permeabilization; clinical translation; deep learning; deep learning algorithm; deep learning model; design; detection sensitivity; diagnostic accuracy; disability; endovascular thrombectomy; human imaging; imaging modality; improved; mortality; multimodality; novel; perfusion imaging; predict clinical outcome; radio frequency; risk prediction; risk/benefit ratio; standard care; stroke patient; stroke therapy; targeted treatment; thrombolysis; time use; transmission process; treatment effect

ABSTRACT Ischemic stroke is one of the leading causes of morbidity and mortality in the U.S. The goal of acute ischemic stroke therapy is to salvage tissue that is at risk of infarction, but still viable, through the use of reperfusion strategies. Current reperfusion therapies are limited by a tight time window for treatment and by the potential risk of brain hemorrhage. Using this time-based approach, only a limited number of stroke patients are eligible for treatment. Patients who present beyond the standard treatment time windows can benefit from therapy when identified based on multimodal MRI; however, precise and accurate identification of the salvageable tissue is essential, as the potential beneficial effect of treatment must be weighed against the risk of hemorrhage. Although a diffusion/perfusion MRI mismatch has been suggested as a guide with which to identify the presence of salvageable tissues and to serve as a selection marker for thrombolysis, the results of clinical trials using this criterion have been inconclusive, in part because of the inclusion of regions of oligemia in the penumbra, which overestimates the size of the tissue at risk. Amide proton transfer (APT) MRI has shown promise in detecting such an acidosis-based ischemic penumbra in animal models and in human stroke patients. However, most currently used APT imaging protocols are not very practical and not optimized with respect to the magnitude of signal changes caused by the pH effect. More quantitative APT-MRI typically would require an even longer scan time due to the use of multiple RF saturation frequencies, multiple acquisitions, and a long RF saturation pulse (or pulse train), all of which hamper clinical translation due to the very small time-window between stroke onset and possible thrombolysis treatment. Our long-term goal is to develop an ultrafast pH imaging technique for routine clinical use to guide reperfusion therapies for hyperacute stroke patients at various therapeutic time windows, as well as predict the risk of hemorrhagic transformation (HT) following acute ischemic stroke. The first clinical hypothesis is that, similar to animal studies, the pH imaging penumbra due to ischemic tissue acidosis predicts the maximum final infarction size if no reperfusion is initiated. Our second clinical hypothesis is that the presence of severe tissue acidosis in the ischemic core is associated with an increased probability of secondary HT. Our hypotheses will be tested through three specific aims: 1) to develop and optimize an ultrafast quantitative pH imaging method; 2) to validate this technique and assess the diagnostic accuracy of the acidosis-based ischemic penumbra in a clinical setting; and 3) to develop a novel deep-learning model with which to predict HT following acute ischemic stroke, and quantify the sensitivity and specificity of pH imaging. This work is expected to accelerate the translation of APT-MRI into a clinically viable and robust method. The addition of pH imaging to the standard MRI protocol is expected to enable better visualization of the true ischemic penumbra, thus improving predictions of clinical outcome and reducing the incidence of HT.

摘要 缺血性中风是美国发病率和死亡率的主要原因之一。 中风治疗是通过使用再灌注来挽救处于梗死风险但仍然存活的组织， 战略布局目前的再灌注治疗受到治疗时间窗紧和潜在风险的限制。 脑出血使用这种基于时间的方法，只有有限数量的中风患者有资格接受 治疗在以下情况下，超过标准治疗时间窗的患者可从治疗中获益： 基于多模态MRI识别;然而，精确和准确地识别可挽救的组织， 这是必要的，因为治疗的潜在有益效果必须与出血风险相权衡。 尽管弥散/灌注MRI不匹配已被建议作为识别存在的指南， 的可挽救组织，并作为溶栓的选择标记，临床试验的结果，使用这个 标准一直是不确定的，部分原因是包括在半影区， 高估了危险组织的大小酰胺质子转移（APT）MRI在检测 这种基于酸中毒的缺血半暗带在动物模型和人类中风患者中。但大多数 当前使用的APT成像协议不是非常实用 由pH效应引起的信号变化。更定量的APT-MRI通常需要更长的扫描时间 由于使用多个RF饱和频率、多次采集和长RF饱和脉冲， (or脉冲序列），由于中风发作之间的时间窗非常小，所有这些都妨碍了临床转化 以及可能的溶栓治疗。我们的长期目标是开发超快pH成像技术， 指导超急性卒中患者在不同治疗时间的再灌注治疗的常规临床应用 窗口，以及预测急性缺血性卒中后出血性转化（HT）的风险。第一 临床假设是，与动物研究相似，由于缺血性组织酸中毒， 如果不开始再灌注，预测最大最终梗死面积。我们的第二个临床假设是， 缺血核心中严重组织酸中毒的存在与继发性 HT。我们的假设将通过三个具体目标进行测试：1）开发和优化超快定量 pH成像方法; 2）验证该技术并评估基于酸中毒的诊断准确性 临床环境中的缺血半暗带; 3）开发一种新的深度学习模型来预测HT 急性缺血性卒中后，并量化pH成像的敏感性和特异性。这项工作预计 加速将APT-MRI转化为临床可行且稳健的方法。添加pH成像 标准MRI方案有望更好地显示真正的缺血半暗带，因此 改善临床结果的预测并降低HT的发生率。